A Retrospective Analysis Of The Efficacy And Safety Of Infliximab In Crohn’s Disease

Objective To evaluate the efficacy and safety of infliximab in Crohn’s disease.Methods Between October2010and March2013relevant clinical data of CD patients treated with infliximab in the Department of Gastroenterology,The Second Xiangya Hospital of Central South University were collected and the efficacy and safety of infliximab were retrospectively analyzed. The data was analyzed using t test. A total of38paxients were enrolled in this study,25males and13females; the mean age was28.1±9.2years (13-55years). The dosage of IFX was5mg/kg at week0,2,6to induce remission, and every8weeks on maintenance therapy. Of38patients,32patients were active CD,6were fistula CD.Results(1) At day1, of32active cases, clinical symptoms of12cases relieved,remission rate was37.5%.(2) At week10,of32active cases,25cases achieved clinical remission,7cases achieved clinically effective. Crohn’S disease activity index(CDAI)(130.3±24.4) of week10decreased compared with that of week0(222.2±41.2)(P<0.001).13patients in maintenance therapy continued effective. (3) Plt、CRP and WBC of week10to14decreased compared with that of week0,while Hb and Alb increased.(4)12patients reviewed by endoscopy after infliximab therapy, after therapy the simple endoscopic score for Crohn’s disease(SES-CD)(4.6±3.1) decreased compared with that before treatment (12.2±7.0)(P=0.001),50%patients achived mucosal healing.(5)6patients with fistula dropped out were effective during the induction therapy,5patients sustained effective during the maintenance therapy.(6)15times of adverse events were found in10patients, infusion reaction and infection were more common.1case developed anaphylactic shock, two cases with active pulmonary tuberculosis, and1case with severe lung infection.Conclusion Infliximab can rapidly improve clinical symptoms and with good safety. The effects in mucosal healing and fistula closure may occur at early medication.